Dr Atulraj Sinha, Manager Effectual Services on Cancer Treatment India and Global.

New Delhi, February 14, 2019:  Oncology domain has always been priority for big pharmaceutical companies globally. Even though the stakes are very high in R&D for cancer treatments, still oncology treatments have assured highest returns for Pharmaceutical companies. Most of the top selling drugs globally are meant for cancer treatments. For past many years, big pharma companies have either acquired or collaborated with other pharma companies to enhance their cancer drug pipeline. The recent one being Bristol Myers Squibb (BMS) acquiring Celgene.

Lately, we have seen lot of new treatments for cancer which includes CAR-T cell therapy, CRISPR/Cas9 therapy etc. In fact, scientists from Israel have claimed to come up with complete cure for cancer, which would be cheap, effective and with no or minimal side effects based on peptide display techniques. However, fraternity belonging to oncology field are skeptical about the claims made by the scientists from Israel because they have provided only limited information.

If we consider India in perspective of cancer patients & treatments, it accounts for 7 of every 100 new cancers cases in the world & inclination towards urbanization will lead to further increase in these figures in future. It is one of the major market for cancer drugs, but still deprived of new drugs or technologies which is mainly due to :

–          Restriction on use of new therapies in oncology,

–          Expensive cancer drugs

–          Lack of  specialized surgical & medical oncologists in India &

–          Poor infrastructure to treat high incidence of cancer in India.

Corporate Comm India(CCI NewsWire)